ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1189

Evaluating Neuropathic and Nociplastic Pain in Patients with Hip and Knee Osteoarthritis

Carly Conran1, Larry Moreland2, Andrew Clauw1, Jennifer Seifert1, Carson Keeter3, Craig Hogan1 and Michael Dayton1, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2University of Colorado, Denver, CO, 3University of Colorado, Aurora, CO

Meeting: ACR Convergence 2023

Keywords: Arthroplasty, fibromyalgia, Osteoarthritis, pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1183–1199) Osteoarthritis – Clinical Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Chronic pain in patients with hip and knee osteoarthritis (OA) has been classically attributed to nociceptive pain pathways. Emerging evidence has demonstrated influence from additional pain pathways in OA (Table 1). In this study, we screened for pre-operative neuropathic and nociplastic pain in patients who subsequently underwent hip or knee arthroplasty.

Methods: Participants filled out two surveys reflecting pre-surgical pain: 1) the PainDETECT questionnaire (PD-Q) to assess neuropathic pain, and 2) the Fibromyalgia Survey Questionnaire (FSQ). The FSQ is comprised of the Widespread Pain Index (WPI) assessing widespread musculoskeletal pain and the Symptom Severity Scale (SSS) assessing comorbid symptoms (e.g., fatigue). The 2016 fibromyalgia criteria were used as inclusion criteria for fibromyalgia diagnosis.

Results: Overall, 89 participants were included in our analysis (23 hip OA, 66 knee OA). The mean age was 66.0 ± 9.01 (mean ± SD), 50 were female (56.2%), 84 were Caucasian Non-Hispanic (94.4%), the mean BMI was 30.43 ±5.56 (Table 2). Of this cohort, 18.0% had widespread pain (WPI ≥ 7), 7.9% met diagnostic criteria for fibromyalgia, 25.8% had possible neuropathic pain (PD-Q 13-18), and 12.4% had probable neuropathic pain (PD-Q ≥19) (Figure 1). This represented 34 (38.2%) unique individuals. We did not find significant differences in age, BMI, sex or site of OA among those with versus without widespread pain, fibromyalgia or neuropathic pain.

Conclusion: Among patients with hip or knee OA who underwent joint arthroplasty, more than a third had evidence of pre-operative nociplastic and/or neuropathic pain. This has clinical relevance, as nociplastic and neuropathic pain may have decreased responsiveness to peripherally directed therapies such as surgery. Given the evidence that there are multiple mechanisms of pain within individuals, this implies a need for multiple therapeutic targets in many patients. Elucidating these pain pathways in future studies will be key to more effectively treating hip and knee OA pain.

Supporting image 1

Table 1. Pain Mechanism Definitions

Supporting image 2

Table 2. Demographics

Supporting image 3

FIgure 1. Incidence of Nociplastic and Neuropathic Pain Among Patients with Hip and Knee OA


Disclosures: C. Conran: None; L. Moreland: Boehringer-Ingelheim, 12, member of independent Data Safety Monitoring Board, Celltrion, 12, member of independent Data Safety Monitoring Board; A. Clauw: None; J. Seifert: None; C. Keeter: None; C. Hogan: None; M. Dayton: None.

To cite this abstract in AMA style:

Conran C, Moreland L, Clauw A, Seifert J, Keeter C, Hogan C, Dayton M. Evaluating Neuropathic and Nociplastic Pain in Patients with Hip and Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/evaluating-neuropathic-and-nociplastic-pain-in-patients-with-hip-and-knee-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-neuropathic-and-nociplastic-pain-in-patients-with-hip-and-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology